CACNA1A and psoriasis: Although the exact molecular mechanisms and appropriate long-term risk-benefit effects need further study, the inhibitory effects of MHP1-AcN on IMQ-induced psoriasis and RANKL-induced osteoclast activation make it a promising agent for psoriatic diseases.